From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing neuroimaging and pharmacological mechanisms without systematic review methodology
PubMed 39098738 · doi:10.1016/j.neubiorev.2024.105841
What was done
The authors conducted a narrative review synthesizing literature on the pharmacodynamics of stimulant medications for attention-deficit/hyperactivity disorder (ADHD). The review focused on bridging synaptic mechanisms with systems-level brain function, specifically emphasizing nuclear medicine and magnetic resonance imaging (MRI) findings regarding acute and prolonged stimulant administration.
What was found
The abstract reports no quantitative values or effect sizes. Qualitatively, stimulant-induced modulation of dopamine and norepinephrine neurotransmission is reported to optimize task-related brain networks, increase perceived saliency, and reduce interference from the default mode network. Acute stimulant exposure may reduce alterations in fronto-striato-parieto-cerebellar networks observed in untreated individuals, whereas the effects of prolonged treatment remain controversial.
Why it matters
This review maps cellular catecholaminergic pharmacodynamics onto macroscale human brain network modulation, helping explain how molecular mechanisms produce clinical improvements in ADHD.
Limits
The paper is a narrative review that reports no sample size or systematic search protocol. The underlying neuroimaging studies reviewed are noted to be limited by small sample sizes, short or absent follow-up periods, and substantial methodological heterogeneity.
Cited by
- supports Prescription stimulants such as Adderall and Vyvanse are amphetamines that primarily release catecholamines, mainly dopamine and epinephrine.